Variation Biotechnologies gains $35M in first round

Clarus Ventures has led a $35.7 million first round for Canada's Variation Biotechnologies. The biotech company's lead candidate is a new vaccine for influenza. ARCH Venture Partners and 5AM Ventures also took part in the round.

- here's the release on the venture round

ALSO: Horizon Therapeutics has raised an additional $15 million through a Series B financing to advance its lead product HZT-501, a "GI-friendly" prescription NSAID, into pivotal Phase III clinical trials in the first half of this year. Scale Venture Partners, formerly known as BA Venture Partners, led the round with Sutter Hill Ventures and Pequot Ventures also participating. Horizon completed a $6 million Series A round in October 2005 with the same syndicate of investors. Release 

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.